论文部分内容阅读
为探讨重组人生长激素 (rhGH)在肝癌患者中的适用问题 ,采用放射配体法对 32例原发性肝癌 (HCC)组织进行了生长激素受体 (GHR)的检测。结果在 2 8例HCC组织检测到GHR ,GHR受体结合容量 (RT)为 (18 430 0± 4 16 33)fmol/mg蛋白 ,平衡解离常数 (Kd)为 (0 6 432± 0 196 1)nmol/L ,与正常肝组织相比 ,其RT降低 (P <0 0 5 ) ,Kd无显著性改变 (P >0 0 5 ) ;HCC组织GHR的结合容量与肿瘤大小呈负相关 ,而与肿瘤分化程度、患者是否合并肝硬化无明显相关 ;有 4例肝癌组织未检测到GHR存在。研究提示 :大多数原发性肝癌组织仍表达低水平GHR ,在其功能未明的情况下 ,rhGH在肝癌患者中的使用应慎重。
In order to investigate the application of recombinant human growth hormone (rhGH) in patients with hepatocellular carcinoma, 32 cases of primary liver cancer (HCC) tissue were tested for growth hormone receptor (GHR) using radioligand method. Results GHR was detected in 28 HCC tissues. The GHR receptor binding capacity (RT) was (18 430 0 ± 4 16 33) fmol/mg protein and the equilibrium dissociation constant (Kd) was (0 6 432± 0 196 1). ) nmol/L, compared with the normal liver tissue, its RT decreased (P <0 05), Kd no significant change (P> 0 05); HCC tissue GHR binding capacity and tumor size was negatively correlated, and There was no significant correlation between the degree of tumor differentiation and whether the patient was associated with cirrhosis; GHR was not detected in 4 cases of hepatocellular carcinoma. Research Tips: Most primary liver cancer tissues still express low levels of GHR. In the case of unknown function, rhGH should be used with caution in patients with liver cancer.